Millipore Sigma Vibrant Logo

119140 Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: (2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide

View Products on Sigmaaldrich.com
119140
가격 및 재고 조회

개요

Replacement Information

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
119140-10MGCN
재고 정보 검색...
—
현재 재고 없음 현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      		 Glass bottle 10 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      —
      가격 문의
      		 —
      Description
      OverviewA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
      Catalogue Number119140
      Brand Family Calbiochem®
      Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
      References
      ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
      Product Information
      CAS number35920-39-9
      FormWhite solid
      Hill FormulaC₁₂H₁₆N₆O₄
      Chemical formulaC₁₂H₁₆N₆O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Target K<sub>i</sub>14 nM
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      119140-10MGCN 04055977223354

      Documentation

      Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Adenosine Receptor Agonist, NECA - CAS 35920-39-9 - Calbiochem Certificates of Analysis

      TitleLot Number
      119140

      References

      참고문헌 보기
      Forster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-September-2019 JSW
      Synonyms(2S,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide
      DescriptionA cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (Ki = 14 nM, 20 nM, 2.4 µM and 6.2 nM for A1, A2A, A2B, A3, respectively). Increases intracellular cAMP production (EC50 = 3.1 µM in A2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number35920-39-9
      Chemical formulaC₁₂H₁₆N₆O₄
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (50 mM)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesForster, K., et al. 2006. Basic Res. Cardiol. 101, 319.
      de Zwart, M., et al. 1998. Nucleosides Nucleotides. 17, 969.
      Phillis, J. et al. 1986, Pharm. Biochem. Behavior.24, 263
      Durcan, M. J., et al. 1989. Pharmacol Biochem Behav. 32, 487.
      Bacher, S., et al. 1982. Naunyn Schmiedebergs Arch Pharmacol. 329, 67.
      Cusack, N., et al. 1981. Br J Pharm.72, 443.
      Londos, C., et al. 1980. Proc Natl Acad Sci.77, 2551.